Eva Wesley, Author at Born2Invest

Eva Wesley

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Eva Wesley

Stories By Eva Wesley

Oryzon Genomics Increases its Half-Year Losses by 83%, to Over 1 Million Euros

PharmaMar Reduces its Profit by 45% in Q1, Rovi Reduces Income by 14%

Made of Genes Is Looking to Expand to the US and the Middle East and Grow by 50% in 2024

Integra Therapeutics Will Receive 10.5 Million for Its Ficat Platform

Vytrus Biotech Increases Sales By 28% Until June and EBITDA By 40%

Grifols Falls 2% on the Ibex 35 After Moody’s Stops Covering It

Cantabria Labs Opens a New R&D&I Centre in Madrid

Esteve Completes the Purchase of HRA Pharma Rare Diseases for 275 Million

Viva in Vitro Raises 1.3 Million Euros to Develop Treatments Against Sepsis

Grifols and Gotham Agree to Extend Trial Deadlines: Grifols Rises 3.3% on the Stock Market